Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Informed reasoning: repositioning of nitisinone to treat oculocutaneous albinism
Prashiela Manga, Seth J. Orlow
Prashiela Manga, Seth J. Orlow
Published September 26, 2011
Citation Information: J Clin Invest. 2011;121(10):3828-3831. https://doi.org/10.1172/JCI59763.
View: Text | PDF
Commentary Article has an altmetric score of 3

Informed reasoning: repositioning of nitisinone to treat oculocutaneous albinism

  • Text
  • PDF
Abstract

Oculocutaneous albinism (OCA) is a group of genetic disorders characterized by hypopigmentation of the skin, hair, and eyes. Affected individuals experience reduced visual acuity and substantially increased skin cancer risk. There are four major types of OCA (OCA1–OCA4) that result from disruption in production of melanin from tyrosine. Current treatment options for individuals with OCA are limited to attempts to correct visual problems and counseling to promote use of sun protective measures. However, Onojafe et al., reporting in this issue of the JCI, provide hope for a new treatment approach for OCA, as they demonstrate that treating mice that model OCA-1b with nitisinone, which is FDA approved for treating hereditary tyrosinemia type 1, elevates plasma tyrosine levels, and increases eye and hair pigmentation.

Authors

Prashiela Manga, Seth J. Orlow

×

Figure 2

Tyrosine catabolism.

Options: View larger image (or click on image) Download as PowerPoint
Tyrosine catabolism.
Five enzymes catalyze the cascade that leads to the...
Five enzymes catalyze the cascade that leads to the degradation of tyrosine, and dysfunction of these enzymes leads to diseases of variable severity (reviewed in ref. 21). Tyrosine is converted to 4-hydroxyphenylpyruvate (HPP) by tyrosine aminotransferase (TAT). Mutations of this enzyme lead to HT-2. HPP is converted to homogentisic acid (HA) by hydroxyphenylpyruvate oxidase (HPD), the target of nitisinone. HPD mutations result in HT-3. HA is converted to 4-maleylacetoacetate (by homogentisate 1,2-dioxygenase [HGD], mutations of which cause alkaptonuria) then fumarylacetoacetate (by malelylacetoacetate isomerase [MAI]). These metabolites are toxic and accumulate, leading to the symptoms common in HT-1 (due to mutations of FAH), which converts fumaryl acetate to fumarate and acetoacetate.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
24 readers on Mendeley
See more details